The first tranche of Singapore’s $10 million grant arrived in Arcturus Therapeutics’ accounts on March 9, delivering $3 million that the company is using to purchase GMP‑grade reagents, conduct animal toxicology studies and begin small‑scale production runs. The Economic Development Board approved the funding only eight weeks after China released the viral genome, a period when local transmission was rising across Southeast Asia. Officials in the city‑state sought a backup plan that would not rely on the large European vaccine manufacturers and could be produced domestically if global supply chains were disrupted. Arcturus proposed a self‑replicating RNA construct.
Pre‑clinical data showed that this platform generates roughly thirty times more viral antigen per microgram of material than conventional messenger RNA vaccines. That difference translates into smaller vials, faster manufacturing cycles and a lower cost per dose—factors that are significant for a nation aiming to immunize about six million residents and guest workers.
Joseph Payne, Arcturus’ chief executive, briefed investors on March 11, explaining that the company’s STARR technology keeps the body’s innate immune sensors active, potentially eliminating the need for a booster dose. He said, “What we bring to the equation here is a single‑shot solution and a 30‑fold improvement in dosing. That is why Singapore selected us.” The grant is released in milestone‑linked tranches rather than as an unrestricted fund; Singapore retains ownership of any resulting product while permitting global commercialization.
Arcturus will collaborate with Duke‑NUS Medical School and the National University of Singapore to advance the candidate from laboratory experiments to clinical testing. For Singapore, the deal strengthens supply‑chain security and accelerates timelines, allowing a nimble manufacturing platform to operate inside the country’s own biotech facilities without waiting for overseas shipments or depending on foreign factories that might cease operations during a crisis.
For Arcturus, the $10 million commitment from a sovereign‑wealth fund provides both cash and credibility, but it also imposes a strict schedule. Failure to meet the agreed milestones would halt further disbursements. The arrangement highlights a broader shift in vaccine financing, where governments are extending support typically reserved for large pharmaceutical firms to smaller biotech companies.
The EDB chose a California‑based startup over established players, betting on a technology that promises a single injection, lower raw‑material usage per dose and rapid scale‑up. While animal results are encouraging, they do not guarantee success in humans; the definitive test will come when the vaccine enters clinical trials.
Singapore’s funding is intended to carry Arcturus to that stage, after which outcomes will depend on scientific data. Other nations are observing the partnership; a positive result could spur similar agreements, whereas a setback might prompt a search for alternative solutions. Singapore has hedged its risk by backing multiple approaches, with this project representing one component of a larger portfolio.
The initial $3 million has already been spent. The next tranche will be released once Arcturus reaches its subsequent development milestone.
At present, the company answers to Singapore’s Economic Development Board, Duke‑NUS, the National University of Singapore and the six million people awaiting a vaccine.
